Resolution

After six years of legal debate involving upwards of 40 attorneys at one point in the trial, the lawsuit and counterclaim were settled out of court.

• Glaxo received an undisclosed payment in exchange for granting exclusive worldwide rights to Emory and Triangle for the clinical trail data and intellectual property related to FTC.
• Emory retained the rights to both 3TC and FTC, thereby securing the intellectual property of their inventors.
• Glaxo and Shire obtained exclusive licenses from Emory to 3TC.
• Triangle Pharmaceuticals was able to keep its license to FTC, which is now commercialized by Gilead Sciences as a result of their purchase of Triangle.

Emory University's involvement and support of its researchers in this case is reflected in its results: their intellectual property is intact, their researchers still happily in their employment, they have functional, ongoing relationships with their defendants and counterclaimants and are able to facilitate and cultivate continued research that is impacting the quality of lives both in the U.S. and worldwide. Emory University continues to be a recognized leader in worldwide HIV/AIDS research, with more than 100 faculty members drawn from diverse departments contributing to Emory's Center for AIDS Research.